278 related articles for article (PubMed ID: 33559780)
1. Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis.
Liu M; Xie F; Liu M; Zhang Y; Wang S
Breast Cancer Res Treat; 2021 Apr; 186(3):591-605. PubMed ID: 33559780
[TBL] [Abstract][Full Text] [Related]
2. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis.
Baretta Z; Mocellin S; Goldin E; Olopade OI; Huo D
Medicine (Baltimore); 2016 Oct; 95(40):e4975. PubMed ID: 27749552
[TBL] [Abstract][Full Text] [Related]
3. BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis.
Zhu Y; Wu J; Zhang C; Sun S; Zhang J; Liu W; Huang J; Zhang Z
Oncotarget; 2016 Oct; 7(43):70113-70127. PubMed ID: 27659521
[TBL] [Abstract][Full Text] [Related]
4. Breast-conserving therapy for breast cancer with BRCA mutations: a meta-analysis.
Wang C; Lin Y; Zhu H; Zhou Y; Mao F; Huang X; Zhou X; Cao X; Sun Q
Breast Cancer; 2022 Mar; 29(2):314-323. PubMed ID: 34766244
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of Androgen Receptor Expression in Triple Negative Breast Cancer: A Systematic Review and Meta-Analysis.
Xu M; Yuan Y; Yan P; Jiang J; Ma P; Niu X; Ma S; Cai H; Yang K
Clin Breast Cancer; 2020 Aug; 20(4):e385-e396. PubMed ID: 32139270
[TBL] [Abstract][Full Text] [Related]
6. Association of Obesity With Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis.
Lohmann AE; Soldera SV; Pimentel I; Ribnikar D; Ennis M; Amir E; Goodwin PJ
J Natl Cancer Inst; 2021 Nov; 113(11):1465-1475. PubMed ID: 33620467
[TBL] [Abstract][Full Text] [Related]
7. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
[TBL] [Abstract][Full Text] [Related]
8. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer.
Sønderstrup IMH; Jensen MB; Ejlertsen B; Eriksen JO; Gerdes AM; Kruse TA; Larsen MJ; Thomassen M; Laenkholm AV
Acta Oncol; 2019 Mar; 58(3):363-370. PubMed ID: 30614364
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis.
Gonzalez-Conchas GA; Rodriguez-Romo L; Hernandez-Barajas D; Gonzalez-Guerrero JF; Rodriguez-Fernandez IA; Verdines-Perez A; Templeton AJ; Ocana A; Seruga B; Tannock IF; Amir E; Vera-Badillo FE
Cancer Treat Rev; 2018 Jan; 62():1-8. PubMed ID: 29126017
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes.
De Talhouet S; Peron J; Vuilleumier A; Friedlaender A; Viassolo V; Ayme A; Bodmer A; Treilleux I; Lang N; Tille JC; Chappuis PO; Buisson A; Giraud S; Lasset C; Bonadona V; Trédan O; Labidi-Galy SI
Sci Rep; 2020 Apr; 10(1):7073. PubMed ID: 32341426
[TBL] [Abstract][Full Text] [Related]
12. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings.
Houts AC; Olufade T; Shenolikar R; Walker MS; Schwartzberg LS
Cancer Treat Res Commun; 2019; 19():100121. PubMed ID: 30785027
[TBL] [Abstract][Full Text] [Related]
14. Risk of seizures in a population of women with BRCA-positive metastatic breast cancer from an electronic health record database in the United States.
Liede A; Sebby W; Miriyala AKR; Potluri R; Mazumder D; Ghosh A; Papademetriou E; Kilpatrick R; Tyczynski JE
BMC Cancer; 2023 Jan; 23(1):78. PubMed ID: 36690978
[TBL] [Abstract][Full Text] [Related]
15. Impact of BRCA Mutation Status on Survival of Women With Triple-negative Breast Cancer.
Yadav S; Ladkany R; Yadav D; Alhalabi O; Khaddam S; Isaac D; Cardenas PY; Zakalik D
Clin Breast Cancer; 2018 Oct; 18(5):e1229-e1235. PubMed ID: 29402697
[TBL] [Abstract][Full Text] [Related]
16. Pregnancy After Breast Cancer in Patients With Germline
Lambertini M; Ameye L; Hamy AS; Zingarello A; Poorvu PD; Carrasco E; Grinshpun A; Han S; Rousset-Jablonski C; Ferrari A; Paluch-Shimon S; Cortesi L; Senechal C; Miolo G; Pogoda K; Pérez-Fidalgo JA; De Marchis L; Ponzone R; Livraghi L; Estevez-Diz MDP; Villarreal-Garza C; Dieci MV; Clatot F; Berlière M; Graffeo R; Teixeira L; Córdoba O; Sonnenblick A; Luna Pais H; Ignatiadis M; Paesmans M; Partridge AH; Caron O; Saule C; Del Mastro L; Peccatori FA; Azim HA
J Clin Oncol; 2020 Sep; 38(26):3012-3023. PubMed ID: 32673153
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.
Gao G; Wang Z; Qu X; Zhang Z
BMC Cancer; 2020 Mar; 20(1):179. PubMed ID: 32131780
[TBL] [Abstract][Full Text] [Related]
18. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
Mosele F; Stefanovska B; Lusque A; Tran Dien A; Garberis I; Droin N; Le Tourneau C; Sablin MP; Lacroix L; Enrico D; Miran I; Jovelet C; Bièche I; Soria JC; Bertucci F; Bonnefoi H; Campone M; Dalenc F; Bachelot T; Jacquet A; Jimenez M; André F
Ann Oncol; 2020 Mar; 31(3):377-386. PubMed ID: 32067679
[TBL] [Abstract][Full Text] [Related]
19. Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer.
Domchek SM; Jhaveri K; Patil S; Stopfer JE; Hudis C; Powers J; Stadler Z; Goldstein L; Kauff N; Khasraw M; Offit K; Nathanson KL; Robson M
Cancer; 2013 Apr; 119(7):1344-8. PubMed ID: 23165893
[TBL] [Abstract][Full Text] [Related]
20. Impact of estrogen receptor-β expression on breast cancer prognosis: a meta-analysis.
Liu J; Guo H; Mao K; Zhang K; Deng H; Liu Q
Breast Cancer Res Treat; 2016 Feb; 156(1):149-62. PubMed ID: 26902609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
